Who are iNO's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inomax, intravenous nitroglycerin, Riociguat (Adempas), Hydralazine/Isorsorbide Dinitrate, Nitroglycerin patch, Nitroprusside, Sodium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ino.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

iNO — Competitive Intelligence Brief

iNO (iNO) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled vasodilator. Area: Critical Care / Respiratory.

marketed Inhaled vasodilator Soluble guanylate cyclase Critical Care / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

iNO (iNO) — Wake Forest University Health Sciences. iNO is inhaled nitric oxide gas that dilates pulmonary blood vessels and improves oxygenation in patients with severe respiratory failure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
iNO TARGET	iNO	Wake Forest University Health Sciences	marketed	Inhaled vasodilator	Soluble guanylate cyclase
Inomax	NITRIC OXIDE	Vero Biotech Inc	marketed	Standardized Chemical Allergen [EPC]	Soluble guanylate cyclase	1999-01-01
intravenous nitroglycerin	intravenous nitroglycerin	University of California, San Francisco	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Riociguat (Adempas)	Riociguat (Adempas)	Chinese University of Hong Kong	marketed	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)
Hydralazine/Isorsorbide Dinitrate	Hydralazine/Isorsorbide Dinitrate	Brigham and Women's Hospital	marketed	Vasodilator combination	Vascular smooth muscle (hydralazine); soluble guanylate cyclase (isosorbide dinitrate)
Nitroglycerin patch	Nitroglycerin patch	GF Strong Rehabilitation Centre	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Nitroprusside, Sodium	Nitroprusside, Sodium	Cristália Produtos Químicos Farmacêuticos Ltda.	marketed	Nitrovasodilator	Soluble guanylate cyclase (via nitric oxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled vasodilator class)

Mallinckrodt · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
University of Florida · 1 drug in this class
Wake Forest University Health Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). iNO — Competitive Intelligence Brief. https://druglandscape.com/ci/ino. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab